Naltrexone-3-salicylate (a Prodrug of Naltrexone): Synthesis and Pharmacokinetics in Dogs

@article{Hussain1988Naltrexone3salicylateP,
  title={Naltrexone-3-salicylate (a Prodrug of Naltrexone): Synthesis and Pharmacokinetics in Dogs},
  author={Munir A. Hussain and Eli. Shefter},
  journal={Pharmaceutical Research},
  year={1988},
  volume={5},
  pages={113-115}
}
Naltrexone-3-salicylate (3), a prodrug of naltrexone (1), was prepared by a simple procedure from naltrexone-3-acetylsalicylate (2). The plasma (dog and human) hydrolysis half-life of 3 was found to be approximately 30 min. Compound 2 was previously shown to hydrolyze in dog and human plasma with a fast deacetylation step to 3, followed by slower hydrolysis of 3 to 1 (t1/2, ∼30 min). Oral naltrexone bioavailability was greatly improved (∼30-fold) after oral administration of 3 to dogs, similar… 

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence.

  • R. Dean
  • Biology, Medicine
    Frontiers in bioscience : a journal and virtual library
  • 2005
Oral naltrexone, a nonselective opioid antagonist, is approved for the treatment of alcohol and opioid dependence. However, the efficacy of oral naltrexone is limited by poor patient compliance. To

Prodrugs to Reduce Presystemic Metabolism

It was shown that the variability of systemic exposure after oral dosing was greatest when oral bioavailability was low and, conversely, inter-subject variability was generally low when oralBioavailability was high.

Pharmacokinetics, metabolism, and in vivo efficacy of the antimalarial natural product bromophycolide A.

Bromophycolide A, an inhibitor of drug-sensitive and drug-resistant Plasmodium falciparum, displays a typical small molecule profile with low toxicity and good bioavailability and the potential for future development of 1 and its bioactive ester analogs is demonstrated.

Prodrugs for the improvement of drug absorption via different routes of administration

Main emphasis is placed on the parenteral, oral, transdermal and ocular routes, Mechanisms for drug absorption enhancement and bioavailability assessment, and some other applications of prodrugs are examined.

References

SHOWING 1-5 OF 5 REFERENCES

Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach.

Naltrex one-3-acetylsalicylate hydrolyzed in human and dog plasma with a fast deacetylation step to naltrexone salicylates followed by a slower hydrolysis step tonaltrexOne.

Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.

There was excellent linearity between the administered dose and the area under the plasma concentration-time profile, as well as total urinary recovery of both drug and metabolite.

Naltrexone and cyclazocine. A controlled treatment study.

The controlled data reported supports the clinical impression that naltrexone produces fewer induction side effects than cyclazocine, and indicates that the drug should be considered as a second line treatment for central nervous system disorders.

Studies of EN-1639A (naltrexone): a new narcotic antagonist.

The narcotic antagonist EN-1639A (naltrexone) was studied in 37 heroin addicts and found to be clinically useful, with a low incidence of side effects, lack of toxicity, high degree of acceptability